Abbott's Financial Results Overview
Abbott has released its financial results for the fourth quarter and full year of 2025, showcasing remarkable growth in earnings across several key areas. The data indicates a positive trajectory for the company, setting a solid foundation for the year ahead. Specifically, Abbott reported a fourth-quarter GAAP diluted earnings per share (EPS) of $1.01, while the adjusted diluted EPS reached $1.50, marking a robust increase of 12 percent from previous reports.
Full-Year Performance Highlights
For the entire year, Abbott recorded a GAAP diluted EPS of $3.72, and an adjusted diluted EPS of $5.15, both showing impressive growth rates of 10 percent. The total sales for 2025 amounted to $44.3 billion, reflecting an increase of 5.7 percent from the prior year. These earnings reflect the company's ability to navigate market challenges successfully while continuing to innovate and expand its product offerings.
Fourth-Quarter Sales Growth
The fourth-quarter sales figures also paint an encouraging picture, with a reported sales increase of 4.4 percent, and a 3.0 percent rise on an organic basis. Excluding COVID-19 related testing sales, organic sales growth stands at 3.8 percent. This modest growth in sales also highlights Abbott's strategic moves to focus on core product lines while capitalizing on demand fluctuations.
2026 Financial Projections
Looking ahead, Abbott is optimistic, projecting an organic sales growth ranging from 6.5 percent to 7.5 percent for the full year of 2026. The adjusted diluted EPS for 2026 is projected to fall within the range of $5.55 to $5.80, indicating a 10 percent growth at the midpoint. This growth is underpinned by the anticipated closing of its acquisition of Exact Sciences, which will enhance Abbott's footprint in the rapidly growing cancer diagnostics market.
Strategic Initiatives and Innovations
During 2025, Abbott made significant strides in its product development, securing regulatory approvals that bolster its market position. Notably, Abbott gained U.S. Food and Drug Administration (FDA) approval for its Volt™ PFA System, its first pulsed field ablation system, aimed at improving patient outcomes in electrophysiology. Furthermore, the CE Mark approval for the TactiFlex™ Duo Ablation Catheter demonstrates Abbott’s commitment to innovation, providing advanced treatment solutions for atrial fibrillation patients.
Continued Commitment to Shareholder Returns
Abbott has a long-standing commitment to returning value to its shareholders, recently declaring a quarterly dividend of $0.63 per share, marking the 408th consecutive quarter of dividends. The company has a proud history of increasing its dividend payouts, having done so for 54 years continuously, and is recognized as part of the S&P 500 Dividend Aristocrats Index, which lists companies committed to consistently rewarding their shareholders.
Global Reach and Impact
With around 115,000 employees, Abbott serves customers in more than 160 countries globally. This broad reach allows Abbott to understand and adapt to various market dynamics effectively. Their portfolio spans diagnostics, medical devices, nutrition, and branded generic medicines, positioning Abbott as a leader in the global healthcare landscape.
Frequently Asked Questions
What are Abbott's earnings per share for 2025?
Abbott reported a GAAP diluted EPS of $3.72 and an adjusted diluted EPS of $5.15 for 2025.
How much did Abbott's sales grow in 2025?
Total sales for Abbott in 2025 amounted to $44.3 billion, an increase of 5.7 percent from the previous year.
What is Abbott's EPS projection for 2026?
Abbott projects its adjusted diluted EPS for 2026 to be between $5.55 and $5.80, reflecting an expected growth rate of about 10 percent.
What notable acquisitions or agreements has Abbott made recently?
In November, Abbott announced an agreement to acquire Exact Sciences, enhancing its capabilities in cancer diagnostics.
When was Abbott's last dividend declared?
Abbott declared a quarterly dividend of $0.63 per share on December 12, 2025, continuing its commitment to return value to shareholders.
